According to the Zhitong Finance App, Zhongsheng Beijing Holdings Biotechnology (08247) issued an announcement. It is expected that the Group will have a net loss of RMB 18 million to RMB 22 million for the year ended December 31, 2023, while net profit of about RMB 14.202 million for the year ended December 31, 2022.

According to the announcement, the expected losses during the reporting period were mainly due to changes in domestic and foreign public health prevention and control policies, a decline in market demand; a decrease in the Group's gross profit due to falling product prices due to centralized procurement in the industry; and an increase in research and development expenses invested by the Group in its superior products (such as flow cytometers and supporting reagents).